Carrot Fertility vs Bristol Myers Squibb
Side-by-side comparison of AI visibility scores, market position, and capabilities
Carrot Fertility is a global fertility benefits platform offering employers customizable coverage for IVF, adoption, surrogacy, menopause, and low-cost medication through 50+ countries.
About
Carrot Fertility is a global fertility and family-forming benefits company founded in 2016 by Tammy Sun, raising over $100M to build the most comprehensive employer fertility benefits platform globally. The company offers employers a highly customizable benefits program covering IVF, egg freezing, donor services, adoption, gestational surrogacy, menopause care, and gender-affirming family building across 50+ countries. Carrot operates a digital-first model that connects members with clinical resources, care navigation, and financial support rather than owning a proprietary clinic network. The platform integrates with leading fertility clinics and medication pharmacies to provide members access to vetted care at competitive prices, including a Carrot Rx program that sources fertility medications at significantly below-retail prices. Carrot serves hundreds of employers including major technology companies, professional services firms, and global corporations that want inclusive fertility benefits covering all paths to parenthood. The company competes with Progyny and Kindbody in the US employer fertility benefits market while leading in global coverage for international employers with diverse workforces across multiple countries.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
About
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.